| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-277993 |
|
|
Homo sapiens |
Pancreatic Cancer Cell |
| pmid |
sentence |
| 30312731 |
The androgen receptor (AR), a nuclear receptor that is activated by binding to androgens [1], promotes the development of prostate cancer [2]. Although traditional AR-targeted therapies are initially effective, most tumors progress to hormone-refractory prostate cancer or castration-resistant prostate cancer (CRPC) within a few years [3]. CRPC patients are commonly treated with androgen deprivation therapy (ADT); however, ADT accelerates neuroendocrine (NE) differentiation with an increased anti-apoptotic stimulus that enables tumor resistance to the AR-targeted therapies |
|
3.0
Androgen deprivation therapy
